Research ArticleOriginal Article
Open Access

Cancer-derived exosomal circTMEM56 enhances the efficacy of HCC radiotherapy through the miR-136-5p/STING axis

Li Yuan, Yue Wang, Junjie Cheng, Shilin Lin, Aying Ma, Kunchao Li, Yiming Zheng, Zhaochong Zeng, Aiwu Ke, Chao Gao and Shisuo Du
Cancer Biology & Medicine April 2025, 22 (4) 396-411; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0544

References

  1. 1.↵
    2. Bray F,
    3. Laversanne M,
    4. Sung H,
    5. Ferlay J,
    6. Siegel RL,
    7. Soerjomataram I, et al.
    Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74: 229–63.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Dimitroulis D,
    3. Damaskos C,
    4. Valsami S,
    5. Davakis S,
    6. Garmpis N,
    7. Spartalis E, et al.
    From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world. World J Gastroenterol. 2017; 23: 5282–94.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Mondini M,
    3. Levy A,
    4. Meziani L,
    5. Milliat F,
    6. Deutsch E.
    Radiotherapy-immunotherapy combinations – perspectives and challenges. Mol Oncol. 2020; 14: 1529–37.
    OpenUrlPubMed
  4. 4.↵
    2. Chen LL.
    The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016; 17: 205–11.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. Patop IL,
    3. Kadener S.
    circRNAs in Cancer. Curr Opin Genet Dev. 2018; 48: 121–7.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Zhang PF,
    3. Wei CY,
    4. Huang XY,
    5. Peng R,
    6. Yang X,
    7. Lu JC, et al.
    Circular RNA circTRIM33-12 acts as the sponge of MicroRNA-191 to suppress hepatocellular carcinoma progression. Mol Cancer. 2019; 18: 105.
    OpenUrlPubMed
  7. 7.↵
    2. Zhang PF,
    3. Gao C,
    4. Huang XY,
    5. Lu JC,
    6. Guo XJ,
    7. Shi GM, et al.
    Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma. Mol Cancer. 2020; 19: 110.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Schreiber RD,
    3. Old LJ,
    4. Smyth MJ.
    Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011; 331: 1565–70.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    2. Dunn GP,
    3. Bruce AT,
    4. Ikeda H,
    5. Old LJ,
    6. Schreiber RD.
    Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3: 991–8.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    2. Allison JP.
    Immune checkpoint blockade in cancer therapy: the 2015 Lasker-DeBakey clinical medical research award. JAMA. 2015; 314: 1113–4.
    OpenUrlCrossRefPubMed
  11. 11.↵
    2. El-Khoueiry AB,
    3. Sangro B,
    4. Yau T,
    5. Crocenzi TS,
    6. Kudo M,
    7. Hsu C, et al.
    Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389: 2492–502.
    OpenUrlCrossRefPubMed
  12. 12.↵
    2. Zhu AX,
    3. Finn RS,
    4. Edeline J,
    5. Cattan S,
    6. Ogasawara S,
    7. Palmer D, et al.
    Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19: 940–52.
    OpenUrlCrossRefPubMed
  13. 13.↵
    2. Wei CY,
    3. Zhu MX,
    4. Zhang PF,
    5. Huang XY,
    6. Wan JK,
    7. Yao XZ, et al.
    PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. J Hepatol. 2022; 77: 163–76.
    OpenUrlPubMed
  14. 14.↵
    2. de Mingo Pulido Á,
    3. Gardner A,
    4. Hiebler S,
    5. Soliman H,
    6. Rugo HS,
    7. Krummel MF, et al.
    TIM-3 regulates CD103+ dendritic cell function and response to chemotherapy in breast cancer. Cancer Cell. 2018; 33: 60–74.e6.
    OpenUrlCrossRefPubMed
  15. 15.↵
    2. Xie N,
    3. Cai JB,
    4. Zhang L,
    5. Zhang PF,
    6. Shen YH,
    7. Yang X, et al.
    Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma. Cell Death Dis. 2017; 8: 3205.
    OpenUrlPubMed
  16. 16.↵
    2. Hansen TB,
    3. Jensen TI,
    4. Clausen BH,
    5. Bramsen JB,
    6. Finsen B,
    7. Damgaard CK, et al.
    Natural RNA circles function as efficient microRNA sponges. Nature. 2013; 495: 384–8.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    2. Li T,
    3. Chen ZJ.
    The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J Exp Med. 2018; 215: 1287–99.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    2. Twyman-Saint Victor C,
    3. Rech AJ,
    4. Maity A,
    5. Rengan R,
    6. Pauken KE,
    7. Stelekati E, et al.
    Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015; 520: 373–7.
    OpenUrlCrossRefPubMed
  19. 19.
    2. Rudqvist NP,
    3. Pilones KA,
    4. Lhuillier C,
    5. Wennerberg E,
    6. Sidhom JW,
    7. Emerson RO, et al.
    Radiotherapy and CTLA-4 blockade shape the TCR repertoire of tumor-infiltrating T cells. Cancer Immunol Res. 2018; 6: 139–50.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    2. Dovedi SJ,
    3. Cheadle EJ,
    4. Popple AL,
    5. Poon E,
    6. Morrow M,
    7. Stewart R, et al.
    Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade. Clin Cancer Res. 2017; 23: 5514–26.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    2. Jiang M,
    3. Chen P,
    4. Wang L,
    5. Li W,
    6. Chen B,
    7. Liu Y, et al.
    cGAS-STING, an important pathway in cancer immunotherapy. J Hematol Oncol. 2020; 13: 81.
    OpenUrlCrossRefPubMed
  22. 22.↵
    2. Bakhoum SF,
    3. Ngo B,
    4. Laughney AM,
    5. Cavallo JA,
    6. Murphy CJ,
    7. Ly P, et al.
    Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. 2018; 553: 467–72.
    OpenUrlCrossRefPubMed
  23. 23.
    2. Bakhoum SF,
    3. Landau DA.
    Chromosomal instability as a driver of tumor heterogeneity and evolution. Cold Spring Harb Perspect Med. 2017; 7: a029611.
  24. 24.↵
    2. Dou Z,
    3. Ghosh K,
    4. Vizioli MG,
    5. Zhu J,
    6. Sen P,
    7. Wangensteen KJ, et al.
    Cytoplasmic chromatin triggers inflammation in senescence and cancer. Nature. 2017; 550: 402–6.
    OpenUrlCrossRefPubMed
  25. 25.↵
    2. Xu M,
    3. Ji J,
    4. Jin D,
    5. Wu Y,
    6. Wu T,
    7. Lin R, et al.
    The biogenesis and secretion of exosomes and multivesicular bodies (MVBs): intercellular shuttles and implications in human diseases. Genes Dis. 2022; 10: 1894–907.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords